Merck's Experimental mRNA Melanoma Vaccine Reduces Cancer Recurrence or Death by 42%

Results from the first major clinical trial of an experimental cancer treatment, combining an mRNA vaccine with immunotherapy, demonstrated a 42% reduction in the recurrence of melanoma or death from the disease over two years. This personalized vaccine was designed using samples from patients' tumors to reprogram immune cells to recognize and kill mutated cancerous proteins.